Basic Research - Cancer(구연) (NP-008) 투명 신세포암 환자에서 AKT1 발현과의 상관관계 및 임상적 유효성 강동 경희대학교병원,¹경희의료원 최태수, 유구한, 신용호, 김영빈, 최정혁, 이상협¹, 이동기, 민경은, 전승현¹, 이형래, 이선주¹, 이충현¹, 장성구¹ DNA methylation is a crucial epigenetic mechanism for determining the destiny of a cell. Its upward or downward dysregulation may induce malignant changes in cells. AKT1, one of RAC-alpha serine/threonine-protein kinases, affects cell proliferation and apoptosis. And its altered overexpression may induce the development and progression of various malignancies. Tissue samples from 60 clear cell renal cell carcinoma cases were used for immunohistochemical staining, and patients with low AKT1 expression were compared with those with high AKT1 expression. The Fuhrman grade of patients in the low expression group was significantly lower than that of patients in the high expression group (p=0.021). While the tumor (T), node (N) and metastasis (M) stages of the AKT1 low expression group appeared to be lower compared with those of the AKT1 high expression group; this difference was not statistically significant (T stage, p=0.313; N stage, p=0.526; M stage, p=0.526). Additionally, patients in the low expression group had lower risk of postoperative tumor recurrence compared with those in the high expression group (p=0.020). The results indicate that the high expression of AKT1 is associated with cancer tissue to a greater extent than normal tissue. Although the biological function of AKT1 in clear cell renal cell carcinoma needs to be identified, high AKT1 expression is associated with high Fuhrman grade and worse recurrence free survival in patients with clear cell renal cell carcinoma. keywords : AKT1, Clear cell renal cell carcinoma, Immunohistochemical staining